Alternatives to DisperseBio

AI-driven digital twin of embryo development for cell-based therapies.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Develops a platform for individual drug customization using aptamers for cancer treatment.

Compressing biology to develop the next generation of therapies.

Pioneering precision microbiome therapeutics for oncology using CRISPR and synthetic biology.

Developing a novel small molecule inhibitor for ovarian cancer treatment targeting DIO3.

Clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers.

Develops and launches Padeliporfin VTP therapy for solid tumor treatment.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.

Developing novel therapeutics for rare genetic diseases.

Biopharmaceutical company developing targeted neutrophil nanoparticle platform for chronic diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biopharmaceutical startup developing novel therapies for rare genetic diseases.

AI-powered patient-centric drug simulations to accelerate and de-risk drug development.

Develops a platform for adaptive clinical trial design and closed-loop execution.

Designs proteins with superior properties using computational analysis, evolutionary insights, and AI.

Upcycles food waste into high-value lactic acid using climate-transformative technology.

AI-driven platform for protein-level disease mapping and drug discovery.